^
BIOMARKER:

ATM mutation

i
Other names: ATM, ATA, ATC, ATD, ATDC, TEL1, TELO1, ATM serine/threonine kinase
Entrez ID:
Related biomarkers:
ATM mutation
Prostate Cancer
olaparib
Sensitive: A1 - Approval
ATM mutation
SCCHN
durvalumab + CP-675206
Sensitive: B - Late Trials
ATM mutation
Breast Cancer
ribociclib
Resistant: B - Late Trials
ATM mutation
CLL
obinutuzumab
Resistant: B - Late Trials
ATM mutation
Ovarian Cancer
olaparib
Sensitive: B - Late Trials
ATM mutation
LUAD
olaparib
Sensitive: C1 - Off-label
ATM mutation
Pancreatic Cancer
olaparib
Sensitive: C1 - Off-label
ATM mutation
Pancreatic Ductal Adenocarcinoma
olaparib
Sensitive: C1 - Off-label
ATM mutation
Urothelial Cancer
olaparib
Sensitive: C1 - Off-label
ATM mutation
Biliary Tract Cancer
olaparib
Sensitive: C1 - Off-label
ATM mutation
Solid Tumor
rucaparib
Sensitive: C2 – Inclusion Criteria
ATM mutation
Solid Tumor
BAY1895344
Sensitive: C2 – Inclusion Criteria
ATM mutation
Prostate Cancer
talazoparib
Sensitive: C2 – Inclusion Criteria
ATM mutation
HER2 Negative Breast Cancer
durvalumab
Sensitive: C2 – Inclusion Criteria
ATM mutation
Solid Tumor
avelumab
Sensitive: C2 – Inclusion Criteria
ATM mutation
Solid Tumor
APG-115
Sensitive: C2 – Inclusion Criteria
ATM mutation
Biliary Tract Cancer
toripalimab
Resistant: C3 – Early Trials
ATM mutation
CRC
niraparib
Sensitive: C3 – Early Trials
ATM mutation
Gastroesophageal Junction Adenocarcinoma
Immunotherapy
Sensitive: C3 – Early Trials
ATM mutation
Gastric Adenocarcinoma
Immunotherapy
Sensitive: C3 – Early Trials
ATM mutation
Colon Cancer
Immunotherapy
Sensitive: C3 – Early Trials
ATM mutation
Mantle Cell Lymphoma
venetoclax + ibrutinib
Sensitive: C3 – Early Trials
ATM mutation
SCCHN
durvalumab
Sensitive: C3 – Early Trials
ATM mutation
Prostate Cancer
pembrolizumab
Sensitive: C3 – Early Trials
ATM mutation
Prostate Cancer
GnRH stimulant
Resistant: C3 – Early Trials
ATM mutation
Pancreatic Ductal Adenocarcinoma
gemcitabine + durvalumab + CP-675206
Sensitive: C3 – Early Trials
ATM mutation
Prostate Cancer
avelumab
Sensitive: C3 – Early Trials
ATM mutation
Ovarian Cancer
olaparib + AZD6738
Sensitive: C3 – Early Trials
ATM mutation
NSCLC
Immunotherapy
Sensitive: C3 – Early Trials
ATM mutation
Breast Cancer
ABT-888 + M6620
Sensitive: C4 – Case Studies
ATM mutation
Small Lymphocytic Lymphoma
T-lymphocyte cell therapy
Sensitive: C4 – Case Studies
ATM mutation
CLL
T-lymphocyte cell therapy
Sensitive: C4 – Case Studies
ATM mutation
LUAD
abemaciclib
Sensitive: C4 – Case Studies
ATM mutation
Prostate Cancer
enzalutamide + 177 Lu PSMA-617
Sensitive: C4 – Case Studies
ATM mutation
Breast Cancer
JPI-547
Sensitive: C4 – Case Studies
ATM mutation
CRC
PARP inhibitor
Resistant: D – Preclinical
ATM mutation
LUAD
talazoparib
Sensitive: D – Preclinical